Clinical Outcomes of Low-Dose Methotrexate Therapy as a Second-Line Drug for Intravenous Immunoglobulin-Resistant Kawasaki Disease.

Published in: Yonsei medical journal (2018)

MTX treatment of IVIG-resistant KD resulted in rapid defervescence, improvement of clinical symptoms, and normalization of acute-phase reactants in all patients. Thus, MTX could be a candidate treatment for IVIG-resistant KD.

Keyphrases

low dose
high dose
end stage renal disease
ejection fraction
newly diagnosed
emergency department
peritoneal dialysis
mesenchymal stem cells
patient reported outcomes
physical activity
combination therapy
replacement therapy
cell therapy